H.C. Wainwright initiated coverage of OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) with a “buy” rating and a 12-month price target of €12.00. The stock closed at €6.25 on March 6.
OSE Immunotherapeutics is a French clinical-stage biotechnology company developing novel immunotherapies against both cancer and autoimmune diseases.
“We believe that OSE, by leveraging the company’s unique and expert understanding of the immune system, could become a major player in these fast growing markets,” writes analyst Swayampakula Ramakanth.
The company’s lead product, Tedopi, is a peptide vaccine for the treatment of advanced HLA-A2-positive non-small cell lung cancer and is currently in a registration-directed Phase 3 study.
The company also has several follow-on products in early stages of development, including FR104 for the treatment of autoimmune diseases; Effi-7 for the treatment of ulcerative colitis; and Effi-DEM, a checkpoint modulator for the treatment of cancers.
“We believe that Tedopi, FR104 and Effi-7 all have blockbuster potential and project their revenues to reach €625-million by 2027,” Mr. Ramakanth added.